Transcend Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Transcend Capital Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,842	Closed	-$222K	–	499
2022 Q1	$222K	Sell	4,842 -3,525	-42%	-$168K	0.02%	455
2021 Q4	$512K	Buy	8,367 +1,701	+26%	+$118K	0.05%	296
2021 Q3	$504K	Hold	6,666	–	–	0.05%	295
2021 Q2	$613K	Buy	6,666 +50	+0.8%	+$4.25K	0.09%	187
2021 Q1	$585K	Buy	6,616 +1,629	+33%	+$162K	0.07%	230
2020 Q4	$465K	Buy	4,987 +50	+1%	+$3.98K	0.06%	242
2020 Q3	$315K	Buy	+4,937	New	+$289K	0.06%	206

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Transcend Capital Advisors's ARKG Position: Q2 2022 in Review

Transcend Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 4,842 shares — an estimated $222K sold.

Transcend Capital Advisors first reported a position in ARKG in Q3 2020 and held it in 7 quarters. The position peaked at $613K in Q2 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

Transcend Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
Transcend Capital Advisors sold 4,842 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $222K.
Transcend Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 7 quarters.
Transcend Capital Advisors's ARK Genomic Revolution ETF position peaked at $613K in Q2 2021.
333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Transcend Capital Advisors's 13F filing for Q2 2022, filed 12 Jul 2022.